MA-SMITHERS
Smithers, a leading provider of testing, consulting, information, and compliance services, announces the appointment of Dr. Stewart B. Jacobson, DVM, DACVP, as President of the Smithers Environmental Risk Sciences Division.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005968/en/
Dr. Stewart B. Jacobson, DVM, DACVP, President, Smithers Environmental Risk Sciences Division. (Photo: Business Wire)
Stewart has responsibility for operations and business strategy in North America, the United Kingdom, Europe, and Asia Pacific, overseeing Ecotoxicology, Environmental Fate, Plant and Animal Metabolism, and Chemistry services for the pharmaceutical, crop protection, and industrial and specialty chemical industries. He joins Smithers with over 20 years in toxicology and preclinical research, with roles ranging from staff pathologist to the leader of large multi-site contract research organizations (CROs).
“Stewart is a strategic innovator who is highly respected in the industry for scientific excellence and delivery of services that meet client expectations,” said Susan Shepherd, Group President, Smithers. “His breadth of leadership experience, understanding of regulated markets, and expertise in managing global operations will reinforce our commitment to deliver accurate data, on time, through high-touch relationships.”
Stewart earned his Bachelor of Science in Engineering/Computer Science from University of Illinois, and his Doctor of Veterinary Medicine (DVM) from Tufts University. After completing a residency at the University of Connecticut, he was certified as a Diplomate of the American College of Veterinary Pathologists (DACVP). He is a member of the Society of Toxicologic Pathologists and the Society of Cardiovascular Pathologists. His previous roles included high-level leadership positions at Inotiv, Battelle Memorial Institute, SNBL, Charles River Laboratories, and Covance Laboratories. Prior to his roles in pharmaceutical and medical device testing, he was a software engineer and entrepreneur focused on developing computer models for the space shuttle and building software engineering systems for aerospace and engineering applications.
For more information about Smithers, please visit https://www.smithers.com/
About Smithers:
Founded in 1925 and headquartered in Akron, Ohio, Smithers is a multinational provider of testing, consulting, information, and compliance services. With laboratories and operations in North America, Europe, and Asia, Smithers supports customers in the transportation, life science, packaging, materials, components, consumer, dry commodities, and energy industries. Smithers delivers accurate data, on time, with high touch, by integrating science, technology, and business expertise, so customers can innovate with confidence.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005968/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
L&T Technology Services Joins the MIT Media Lab to Collaborate on AI-led Innovations19.9.2025 10:30:00 CEST | Press release
With access to world-class research and breakthrough problem-solving opportunities, LTTS will explore next-gen technologies in Mobility, Sustainability and Tech L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a multi-year membership agreement with the MIT Media Lab, one of the world’s most prestigious research institutions. As a consortium Lab Member, LTTS intends to explore next-generation advancements in artificial intelligence (AI), underscoring its commitment to driving transformational innovation in Mobility, Sustainability and Tech. As part of the agreement, LTTS will engage in active discussions and information exchange with the Media Lab’s unique cross-disciplinary ecosystem that brings together researchers, innovators and industry leaders. The collaboration not only emphasizes practical AI innovation but also accelerates technology-driven advancements by linking LTTS’ expertise in AI and engineering w
SMBC Group and Jefferies Significantly Expand Their Global Strategic Alliance19.9.2025 10:00:00 CEST | Press release
Joint Venture to Combine Equities and ECM Businesses in JapanExpanding Joint Coverage of Larger SponsorsIn EMEA, Implementing Joint Origination, Underwriting and Execution of Syndicated Leveraged Finance for These ClientsSMBC to Increase Equity Ownership in Jefferies to up to 20% in the Open MarketSMBC to Provide Jefferies Approximately $2.5 Billion in New Credit Facilities to Support Jefferies and to Facilitate Collaboration Efforts Jefferies Financial Group, Inc. (NYSE: JEF) (“Jefferies”) and Sumitomo Mitsui Financial Group, Inc. (NYSE: SMFG) (“SMFG”), Sumitomo Mitsui Banking Corporation (“SMBC”), and SMBC Nikko Securities Inc. (“SMBC Nikko”) (collectively, “SMBC Group”) announced today that they are significantly expanding their Global Strategic Alliance. SMBC Group and Jefferies initially entered into a Strategic Alliance in 2021 to collaborate on future corporate and investment banking business opportunities. In 2023, the Alliance was expanded to enhance collaboration across M&A,
REJO MULTI Unveiled at InterTabac 2025, Featuring Dual-Heating and Cross-Brand Compatibility19.9.2025 10:00:00 CEST | Press release
Flexible brand options, enhanced aroma, and reduced tobacco consumption empower REJO's ambition in Europe REJO, a global heat-not-burn (HNB) pioneer, officially unveiled REJO MULTI device at InterTabac 2025 as one of the exhibition’s most anticipated products. The device introduces a dual-heating system that pairs AirFlow and Round Heating technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919713971/en/ REJO MULTI Product Launch Event “REJO MULTI represents a major step forward in HNB technology,” said Loic Li, the Global Sales Director of REJO. “Its open compatibility allows users to explore multiple brands and flavors with a single device, while our dual-heating system ensures even heating, enhanced aroma delivery, and consistent nicotine satisfaction.” “Our goal with REJO MULTI is to empower users with choice and flexibility, while providing retailers and partners with an innovative, market-ready product that
Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 18:22:00 CEST | Press release
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 17:45:00 CEST | Press release
Celltrion’s Omlyclo™, the first and only omalizumab biosimilar in Europe, will be commercially available starting in Norway, with subsequent rollouts in European countries Results from the global Phase III clinical trial of Omlyclo™ (CT-P39) for the treatment of chronic spontaneous urticaria (CSU), allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented at a satellite symposium during the 2025 European Academy of Dermatology and Venereology (EADV) Congress Celltrion highlights the strength of its expanding dermatology portfolio with positive clinical results for CT-P55, a biosimilar candidate referencing secukinumab With the launch of Omlyclo™, Celltrion underscores its commitment to advancing innovative and accessible treatments in immunology and dermatology Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom